Co-Authors
This is a "connection" page, showing publications co-authored by PENG HUANG and VARSHA V GANDHI.
Connection Strength
0.336
-
Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences. Clin Cancer Res. 1997 Aug; 3(8):1347-55.
Score: 0.039
-
Gemcitabine: preclinical pharmacology and mechanisms of action. Semin Oncol. 1996 Oct; 23(5 Suppl 10):3-15.
Score: 0.037
-
Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res. 1996 Apr; 2(4):653-8.
Score: 0.036
-
Preclinical characteristics of gemcitabine. Anticancer Drugs. 1995 Dec; 6 Suppl 6:7-13.
Score: 0.035
-
Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol. 1995 Aug; 22(4 Suppl 11):3-10.
Score: 0.034
-
Difluorodeoxyguanosine: cytotoxicity, metabolism, and actions on DNA synthesis in human leukemia cells. Semin Oncol. 1995 Aug; 22(4 Suppl 11):61-7.
Score: 0.034
-
Cytotoxicity, metabolism, and mechanisms of action of 2',2'-difluorodeoxyguanosine in Chinese hamster ovary cells. Cancer Res. 1995 Apr 01; 55(7):1517-24.
Score: 0.033
-
Fludarabine inhibits DNA replication: a rationale for its use in the treatment of acute leukemias. Leuk Lymphoma. 1994; 14 Suppl 2:3-9.
Score: 0.031
-
Metabolism and action of 2',2'-difluorodeoxycytidine: self-potentiation of cytotoxicity. Adv Exp Med Biol. 1991; 309A:125-30.
Score: 0.025
-
Metabolism and action of fludarabine phosphate. Semin Oncol. 1990 Oct; 17(5 Suppl 8):3-17.
Score: 0.024
-
Fludarabine: pharmacokinetics, mechanisms of action, and rationales for combination therapies. Semin Oncol. 1993 Oct; 20(5 Suppl 7):2-12.
Score: 0.008